Eli Lilly and Company
KRAS G12C INHIBITORS
Last updated:
Abstract:
The present invention provides compounds of the formula: ##STR00001## where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
Status:
Application
Type:
Utility
Filling date:
4 Dec 2020
Issue date:
17 Jun 2021